Abstract
The irrational use of antimicrobial agents for several decades has led to the drug-resistance among the patient population. Overcoming the present drug-resistance is a major challenge for modern day scientists. In order to counter this problem, several approaches have been utilized, one of which involve drug design and discovery, where new classes or unexplored chemical moieties are explored for a particular activity, either serendipitously or quite rationally.
Highlights
The irrational use of antimicrobial agents for several decades has led to the drug-resistance among the patient population [1]
The final compounds and the intermediates were analyzed using spectroscopic methods: Fourier-Transformed Infrared (FTIR) study, employing on Shimadzu® IRAffinity-1 instrument; 1H-NMR study was performed on Bruker Avance-II instrument, making use of an internal standard, tetramethylsilane; mass studies were executed on MICROMASS Q-TOF instrument
The current exploration helped to design the compounds which have better potency than our previous reports, and providing imperative knowledge regarding the selection of the substituents
Summary
The irrational use of antimicrobial agents for several decades has led to the drug-resistance among the patient population [1]. Overcoming the present drug-resistance is a major challenge for modern day scientists. In our previous research (Part-I of Research), based on the research evidence that phthalimide based compounds have gained adequate attention as anti-infective (anti-fungal, anti-microbial, anti-retroviral, anti-influenza, anti-malarial, and anti-tubercular) very recently [3]. We developed some potential phthalimide based compounds (2-((2-(4-substituted-phenyl) hydrazinyl) methyl) isoindoline-1,3-dione) derived from N-chloromethyl phthalimide by reacting with aromatic hydrazine derivatives and screened for anti-microbial studies against two Citation: Debarshi K M, Mohamad T, Santosh S C. Substituting an Additional 4-(2-Aminoethyl) Aniline Group in Fabricated Isoindoline-
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Drug Designing & Intellectual Properties International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
